About: Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.54 (-1.95%)
IMTX NASDAQ Immatics NV
Immatics NV share price
Atividade de preço de IMTX
Último preço
$ 7,540
Variação (24h)
-0,15 USD (1,95%)
Volume
619.70K
Volume (média 4 sem.)
-
Abertura
$ 7,69
Variação do dia
$ 7,45 - $ 7,76
Fechamento anterior
$ 7,69
Último negócio
22 Oct, 8:13 pm GMT+0
Atrasado
22 Oct, 8:13 pm GMT+0
IMTX price performance
Atrasado
22 Oct, 8:13 pm GMT+0
quote.marketSignals